Cargando…
Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
Objectives: To analyze safety and impact of natalizumab (NTZ) exposure on the disease course, pregnancy, and newborn outcomes of relapsing-remitting multiple sclerosis (RRMS) patients from the Austrian Multiple Sclerosis Treatment Registry (AMSTR). Materials and Methods: Twelve pregnancies of 11 wom...
Autores principales: | Guger, Michael, Traxler, Gerhard, Drabauer, Martina, Leitner-Pohn, Doris, Enzinger, Christian, Leutmezer, Fritz, Oel, Dierk, Di Pauli, Franziska, Berger, Thomas, Ransmayr, Gerhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417297/ https://www.ncbi.nlm.nih.gov/pubmed/32849179 http://dx.doi.org/10.3389/fneur.2020.00676 |
Ejemplares similares
-
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023) -
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023) -
Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry
por: Guger, Michael, et al.
Publicado: (2021) -
COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry
por: Bsteh, Gabriel, et al.
Publicado: (2021) -
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study
por: Bsteh, Gabriel, et al.
Publicado: (2021)